Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
05 Ottobre 2022 - 2:00PM
Business Wire
Adicet to Host R&D Webcast Event on
Thursday, November 10, 2022 at 9:00am EST
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing first in class, allogeneic
chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T
cell therapies today announced four preclinical abstract poster
presentations at the upcoming Society for Immunotherapy of Cancer
(SITC) 37th Annual Meeting taking place November 8-12, 2022 in
Boston, MA.
Poster Presentations:
Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd):
A Newly-Described Approach for Augmenting Potency of γδ T Cell
Immunotherapy Poster/Abstract Number: 198 Presenting
Author: Marissa Herrman, Ph.D. Date/Time:
November 11, 2022 from 9:00am – 9:00pm EST
Title: Preclinical Discovery and Characterization of
Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer
Poster/Abstract Number: 203 Presenting Author: Nitya
S. Ramadoss, Ph.D. Date/Time: November 10, 2022 from
9:00am – 9:00pm EST
Abstract Title: Allogeneic “off-the-shelf” γδ T cells
modified with CD27- containing CAR for targeting CD70+ cancers
Poster/Abstract Number: 246 Presenting Author: Kevin
P. Nishimoto, Ph.D. Date/Time: November 11, 2022 from
9:00am – 9:00pm EST
Abstract Title: Preclinical Discovery and Evaluation of
Allogeneic “off-the-shelf” γδ CAR T Cells Targeting B7-H6+ Tumors
Poster/Abstract Number: 247 Presenting Author: Kevin
P. Nishimoto, Ph.D. Date/Time: November 10, 2022 from
9:00am – 9:00pm EST
The abstracts will be available in a Journal for ImmunoTherapy
of Cancer (JITC) supplement, which will be published on Monday,
November 7 at 8:00am EST on www.sitcancer.org.
R&D Webcast
Adicet will host an R&D webcast presentation on Thursday,
November 10, 2022 at 9:00am EST to provide an overview of its
R&D pipeline.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic chimeric antigen receptor
(CAR) and adaptor (CAd) gamma delta T cell therapies engineered to
enhance selective tumor targeting, facilitate innate and adaptive
anti-tumor immune response, and improve persistence for durable
activity in patients. For more information, please visit our
website at http://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221005005195/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024
